TrialThe Journal of infectious diseases2016

Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.

Robert J O'Connell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.